S P E E D I N G U P P R O G R E S S
Under the aegis of the Bullukian Foundation
CLARA DAY ON OPERATIONS RESEARCH IN
CANCER TREATMENT & OPERATION MANAGEMENT
S P E E D I N G U P P R O G R E S S
Under the aegis of the Bullukian Foundation
November 17, 2010
Organisation des soins en cancérologie, 17 novembre 2010 Sous l'égide de la Fondation Bullukian
Seven Cancer Research Networks within France
• To facilitate and coordinate Cancer research,in particular Translational Research.
• Coordination by French National Cancer Institute (INCa).
Cancer in FranceIncidence 315,000 / yearMortality 150,000 / year
P 2
Under the aegis of the Bullukian FoundationOrganisation des soins en cancérologie, 17 novembre 2010
CLARA: research network organization
European and international dimension
P 3
Organisation des soins en cancérologie, 17 novembre 2010 Sous l'égide de la Fondation Bullukian
CLARA goals
Rapid transferof research to patients
Economic developmentof oncology research
TranslationalCancer Research
P 4
Under the aegis of the Bullukian FoundationOrganisation des soins en cancérologie, 17 novembre 2010
CLARA major partners with international leadership position
CEA-Leti : AtomicEnergy Commission –Electronic and Information Technology LaboratoryCERN: EuropeanOrganization for NuclearResearchCRMN: European Center for High Field NMRELI : EuropeanLymphoma InstituteIARC: International Agency for Research on CancerELuI: European Lung InstitutePARCC-ARA: Support Platform for ClinicalResearch in Oncology in the inter-region Rhône-Alpes AuvergneWSN: World SarcomaNetwork
LYON
GRENOBLECEA-LetiELuI
GENEVA CERN
CRMNELIIARCPARCCWSN
P 5
Under the aegis of the Bullukian FoundationOrganisation des soins en cancérologie, 17 novembre 2010
CLARA major Cancer pathologies with international leadership position
Lymphoma ELI Pr Coiffier – Pr SallesSarcoma WSN Pr BlayLung LCEH Pr Brambilla
Glioblastoma Pr Honnorat – Pr Berger
Hepatocarcinoma Pr Trepo, Pr Zoulim, Pr Merle
1st
order
2nd
order
P 6
Under the aegis of the Bullukian FoundationOrganisation des soins en cancérologie, 17 novembre 2010
CLARA’s whole spectrum of competitive platforms
Metabolomics
Lab benchGenomics - Epigenomics
Experimental cancer modelsBio informatics
Nanotechnologies
Imaging facilities
Pharmacogenomics
Proteomics
Cancer epidemiologyCancer prevention
Clinical researchHadrontherapy
Bio therapiesPatient bed site
€ 50M investment
P 7
Under the aegis of the Bullukian FoundationOrganisation des soins en cancérologie, 17 novembre 2010
European Observatory of Cancer
http://eu-cancer.iarc.fr/
Data about EuropeFrance
P 8
Organisation des soins en cancérologie, 17 novembre 2010 Sous l'égide de la Fondation Bullukian
CLARA Strengths and Key Features
Unique integrated research network focused on oncology in Rhône-Alpes-Auvergne
Brings out, evaluates and assists R&D projects involving interdisciplinary experts at the academic, clinical and private companies level
Flexible, reactive and significant funding thanks to the support of INCa, local authorities, and European funds making possible both the CLARA “Proof of concept” programme and CLARA core projects
Neutral and independent interface towards private investors and research organisations
P 9
Under the aegis of the Bullukian FoundationOrganisation des soins en cancérologie, 17 novembre 2010
CLARA auto-analysis 2007-2010
STRONG POINTSSignificant contribution of CLARA researchers to high-impact journals
Five IBiSA national certifications have been granted to CLARA platforms and three major biological resources centres have been certificated
CLARA Portfolio of 25 Proof of concept projects (€32M) based on academic-clinical-industrial cooperation
Initiation of first class projects for enhanced visibility and attractiveness of research
CLARA mobilises diversified funding resources
P 10
Organisation des soins en cancérologie, 17 novembre 2010 Sous l'égide de la Fondation Bullukian
INCa-funded projects
INCa 2009 Activity Report
P 11
Organisation des soins en cancérologie, 17 novembre 2010 Sous l'égide de la Fondation Bullukian
Synopsis of bibliometric analysis
Quantitative evolution of publications
P 12
100%
110%
120%
130%
140%
2005 2006 2007 2008 2009
Pro
gre
ss
ion
ind
ex
(20
05
as
10
0%
)
year
World
France
CLARA
Organisation des soins en cancérologie, 17 novembre 2010 Sous l'égide de la Fondation Bullukian
Synopsis of bibliometric analysis
Cancéropôles contribution to international visibility
P 13
Organisation des soins en cancérologie, 17 novembre 2010 Sous l'égide de la Fondation Bullukian
CLARA’s Proof of Concept programme
Growth of CLARA projects portfolio
P 14
0
5
10
15
20
25
30
2005 2006 2007 2008 2009 2010
Num
ber o
f pro
ject
s
Year
Completed with Proof of Concept
Completed
Ongoing
Organisation des soins en cancérologie, 17 novembre 2010 Sous l'égide de la Fondation Bullukian
CLARA PoC economical impact
The projects have generated a variety of economic spillovers. 18 start-ups and SMEs have invested €22 M (versus €10M by CLARA), and 11 companies have reached significant “growth milestones”:
5 start-ups have been created: iDD Biotech, EcrinTherapeutics, Fluoptics, Netris Pharma and Synthelis,1 foreign company subsidiary establishment in the region : OncoTherapy Science from Japan,5 companies raised capital (>€40M) : EDAP TMS, EndoControlMedical, ERYtech Pharma, ImmunID Technologies and Nanobiotix,4 companies are listed on the stock exchange or trade sale: EDAP TMS, Genome Express, Innate Pharma (IPO) and OPi.
P 15
Organisation des soins en cancérologie, 17 novembre 2010 Sous l'égide de la Fondation Bullukian
CLARA scientific events
P 16
CLARA organised event co-organised with another Cancéropôle
Under the aegis of the Bullukian FoundationOrganisation des soins en cancérologie, 17 novembre 2010
Priorities for 2011-2014
Further mobilise its network on two priorities: identification and assistance to projects of academic –clinical – industrial partnerships in the field of cancerDevelop synergies with key regional partners and abroad in the frame of project detection, evaluation, maturing and fundingReinforce communication on its strategy, projects and results, especially on the Cancéropôle CLARA’s “Proof of Concept” programmeGain further financial support from INCa, regional authorities, French programmes and European funds to support ambitious projects
P 17
Under the aegis of the Bullukian FoundationOrganisation des soins en cancérologie, 17 novembre 2010
Work plan
P 18
Axis I: “Tumour escape, cell plasticity and targeted therapy”
Axis A: “Evaluation, risk perception and cancer prevention”
Technological platforms and
biological resources centres
Proof of concept
Support to Clinical
Research
Axis II: “Infections and Cancer”
Axis III: “Nanotechnology, imaging and cancer”
Axis B: “Environment, nutrition and cancer”
Axis C: “Hadrontherapy and cancer”
Transverse actions
Priority axes
Emerging axes
Under the aegis of the Bullukian FoundationOrganisation des soins en cancérologie, 17 novembre 2010
CLARA Ambition for 2014
Expand the CLARA Proof of Concept programme in oncology to other European regionsA significant move within its projects from pre-clinical studies to clinical trialsAn increased participation of CLARA teams toEuropean programmes and ambitious initiativesAn acceleration of company creations, development and arrival in the regionA broad-spectrum network of experts providing services to oncology research and patientsA clear visibility of CLARA’s research within the nation and elsewhere in Europe
P 19
Under the aegis of the Bullukian FoundationOrganisation des soins en cancérologie, 17 novembre 2010
Support to Clinical Research
P 20
Information
European Lymphoma Institute (ELI)
ClinicalPARCC-ARA
platform
Support to CLARA’s major
cancer pathologies
PHRC cancer
Data management
Training
World Sarcoma Network (WSN)
European Lung Institute (ELuI)
In support of Measure 4, Cancer Plan II to stimulate clinical research
Under the aegis of the Bullukian FoundationOrganisation des soins en cancérologie, 17 novembre 2010
Project of Evaluation, Risk Perception and Cancer Prevention
P 21
•In support of Measure 2, Cancer Plan II to understand through research and reduce inequalities in relation to cancer•With support of the interregional Regional Resources Centre for Information, Prevention and Education about Cancers (Hygée centre, St-Etienne)
Collective / individual decision-makingQuantitative analysisQualitative analysis
Prevention
Therapeutic management
Primary preventionIdentification of risk factorsPatients’ perception of risks
ScreeningEvaluation of screening programmesDeterminants of participation to screening programmesTargeted interventions in non-participative population
Links
Therapeutic management optimisationHomecarePatients education programmes
Axis III
Axis B
Under the aegis of the Bullukian FoundationOrganisation des soins en cancérologie, 17 novembre 2010
Project of Evaluation, Risk Perception and Cancer Prevention
P 22
Prev
entio
nTh
erap
eutic
m
anag
emen
t
Patients involvement
Health inequalities
Education of intermediaries for cancer mass screening in non-privileged areas Reasons for either participating or not to cancer mass screening
Optimum mapping of various organisational methods according to geographical, epidemiological and demographic situations
Develop a multidisciplinary approachStudy the role and consequences of inequalities rather than their description Participate to the development of methods to evaluate interventions to reduce health inequalities
Economic study on adherence to clinical practice in sarcoma Determinants of therapeutic management for patients with broncho-pulmonar cancer Evaluation of therapeutic management of hospital vs. home chemotherapy
Health inequalities for breast and colon cancer screening